Alzheimer's Association Welcomes FDA Advisory Committee Unanimous Vote of Efficacy of Donanemab for the Treatment of Early Alzheimer's Disease
June 11, 2024
June 11, 2024
CHICAGO, Illinois, June 11 -- The Alzheimer's Association issued the following news release on June 10, 2024:
The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) advisory committee's unanimous finding that donanemab (Eli Lilly) is effective for the treatment of early Alzheimer's disease, which includes mild cognitive impairment and mild Alzheimer's dementia, and that the treatment's benefits outweigh the risks.
If approval is granted by . . .
The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) advisory committee's unanimous finding that donanemab (Eli Lilly) is effective for the treatment of early Alzheimer's disease, which includes mild cognitive impairment and mild Alzheimer's dementia, and that the treatment's benefits outweigh the risks.
If approval is granted by . . .